Jasper Therapeutics, Inc. · NASDAQ:JSPR
Jasper Therapeutics — EAACI Congress 2024
20 slides from Jasper Therapeutics's conference presentation, Jun 1, 2024
Slide 1: EAACI Congress 2024
EAACI Congress 2024 Valencia, Spain 31 May - 3 June Revolutionising Patient Care Through the Power of Data Science ein | | OMe Ray | HEED | ooe@one #EAAClIcongress www.eaaci.org
Slide 2: Phase 1b/2a BEACON Study in Chronic Spontaneous Urticaria
Phase 1b/2a BEACON Study in Chronic Spontaneous Urticaria Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Briquilimab Subcutaneously Administered Prof. Marcus Maurer Professor of Dermatology and Allergy, Head of Dermatological Allergology and Director of Research at th
Slide 3: Disclosure of Conflict of Interest
Disclosure of Conflict of Interest Marcus Maurer is or recently was a speaker and/or advisor for and/or has received research funding from Allakos, Alexion, Alvotech, Almirall, Amgen, Aquestive, argenX, AstraZeneca, Celldex, Celltrion, Clinuvel, Escient, Evommune, Excellergy, GSK, Incyte, Jasper, Ka
Slide 4: Table of Content
Table of Content 1 Mast Cells 2 Briquilimab 3 Trial Design 4 Summary
Slide 5: Mast Cells
1 Mast Cells Chronic urticaria is an inflammatory disease driven by the activation of skin mast cells • Devastating disease characterized by severe itching, hives/wheals, inflammation, and/or angioedema occurring for >6 weeks • Patients suffer numerous physical/psychological symptoms that significan
Slide 6: Mast Cells
1 Mast Cells Mast cells (MCs) are key drivers of the inflammatory response in a number of allergic and dermatologic diseases • MCs are potent drivers of inflammation in skin, lungs and gut • Activated MCs release pro-inflammatory compounds that drive diseases such as CSU, & CIndU • Current approved
Slide 7: Mast Cells
1 Mast Cells Depletion of mast cells by anti-c-Kit monoclonal antibody blockade is a novel approach to treat urticarias • SCF signaling through c-Kit prevents mast cells apoptosis via the Bim-mediated pathway1 • Blockade of c-Kit signaling on MCs leads to apoptosis and phagocytic clearance2 • Partia
Slide 8: Briquilimab
2 Briquilimab Mast cell survival assay Briquilimab blocks c-Kit signaling leading to durable mast cell depletion • Briquilimab is an aglycosylated IgG1 anti c-Kit antibody with high affinity to c-Kit (Kd <5pm) • Briquilimab blocks c-Kit signaling by blocking the SCF ligand binding site on the recept
Slide 9: Briquilimab
2 Briquilimab Skin mast cell depletion 4 weeks after single dose (≥42 mg)1 Single subcutaneous injection of briquilimab Briquilimab Healthy Volunteer Phase 1 Subcutaneous Study significantly depletes human skin MCs • SC dose above 80mg, potently depletes skin MCs • Dose dependent MC depletion • MC d
Slide 10: Briquilimab
2 Briquilimab Pharmacokinetics (≥10 mg)1 Briquilimab Healthy Volunteer Phase 1 Subcutaneous Study Briquilimab pharmacokinetics may enable optimal biologic dosing • Briquilimab is designed to minimize unwanted c- Kit-related effects • Half life = 9 days • Low frequency of ADAs and do not appear to af
Slide 11: Trial Design
3 Trial Design Briquilimab Phase 1b/2a BEACON study in patients with Chronic Spontaneous Urticaria (CSU) • Study Goal: • Identify the optimal therapeutic doses & dosing frequency of SC briquilimab to inform future registrational trials • Key Objectives: • Multiple briquilimab dose levels, and interv
Slide 12: Trial Design
3 Trial Design Phase 1b/2a BEACON Study in Chronic Spontaneous Urticaria Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study
Slide 13: Trial Design
3 Trial Design Phase 1b/2a BEACON Study in Chronic Spontaneous Urticaria Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Screening/Eligibility Study Operations Key Assessments ü Disease Scores: UAS7, UCT • CSU diagnosis ≥ 6 mos. • H1-antihistamine-failed • US Lead: Tom Ca
Slide 14: Trial Design
3 Trial Design Phase 1b/2a BEACON Study in Chronic Spontaneous Urticaria Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Screening/Eligibility Study Operations Key Assessments ü Disease Scores: UAS7, UCT • CSU diagnosis ≥ 6 mos. • H1-antihistamine-failed • US Lead: Tom Ca
Slide 15: Trial Design
3 Trial Design Phase 1b/2a BEACON Study in Chronic Spontaneous Urticaria Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Screening/Eligibility Study Operations Key Assessments ü Disease Scores: UAS7, UCT • CSU diagnosis ≥ 6 mos. • H1-antihistamine-failed • US Lead: Tom Ca
Slide 16: Trial Design
3 Trial Design Phase 1b/2a BEACON Study in Chronic Spontaneous Urticaria Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Screening/Eligibility Study Operations Key Assessments ü Disease Scores: UAS7, UCT • CSU diagnosis ≥ 6 mos. • H1-antihistamine-failed • US Lead: Tom Ca
Slide 17: Trial Design
3 Trial Design Phase 1b/2a BEACON Study in Chronic Spontaneous Urticaria Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Screening/Eligibility Study Operations Key Assessments ü Disease Scores: UAS7, UCT • CSU diagnosis ≥ 6 mos. • H1-antihistamine-failed • US Lead: Tom Ca
Slide 18: Summary
4 Summary • Briquilimab design and characteristics offers a new approach to treatment of MC diseases • Beacon study is enrolling to assess an optimal biologic dosing schedule • Takes advantage of the MC recovery time (over 12 weeks) • Potential to deplete MCs, with durable efficacy and reduced undes
Slide 19: Summary
4 Summary Thank you to the patients and our Beacon investigators in the US and Germany!
Slide 20: EAACI Congress 2024
EAACI Congress 2024 Valencia, Spain 31 May - 3 June Revolutionising Patient Care Through the Power of Data Science ein | | OMe Ray | HEED | ooe@one #EAAClIcongress www.eaaci.org